Do mutations required for adaptation occur de novo, or are they segregating within 34 populations as standing genetic variation? This question is key to understanding adaptive 35 change in nature, and has important practical consequences for the evolution of drug 36 resistance. We provide evidence that alleles conferring resistance to oxamniquine (OXA), an 37 antischistosomal drug, are widespread in natural parasite populations under minimal drug 38 pressure and predate OXA deployment. OXA has been used since the 1970s to treat 39 Schistosoma mansoni infections in the New World where S. mansoni established during the 40 slave trade. Recessive loss-of-function mutations within a parasite sulfotransferase (SmSULT-41 OR) underlie resistance, and several verified resistance mutations, including a deletion 42 (p.E142del), have been identified in the New World. Here we investigate sequence variation in 43 SmSULT-OR in S. mansoni from the Old World, where OXA has seen minimal usage. We 44 sequenced exomes of 204 S. mansoni parasites from West Africa, East Africa and the Middle 45 East, and scored variants in SmSULT-OR and flanking regions. We identified 39 non-46 synonymous SNPs, 4 deletions, 1 duplication and 1 premature stop codon in the SmSULT-OR 47 coding sequence, including one confirmed resistance deletion (p.E142del). We expressed 48 recombinant proteins and used an in vitro OXA activation assay to functionally validate the 49 OXA-resistance phenotype for four predicted OXA-resistance mutations. Three aspects of the 50 data are of particular interest: (i) segregating OXA-resistance alleles are widespread in Old 51 World populations (4.29 -14.91% frequency), despite minimal OXA usage, (ii) two OXA-52 resistance mutations (p.W120R, p.N171IfsX28) are particularly common (>5%) in East African 53 and Middle-Eastern populations, (iii) the p.E142del allele has identical flanking SNPs in both 54
INTRODUCTION
The rate at which drug resistance alleles (or any other beneficial alleles) spread within 76 populations in response to a drug treatment (or any other selection pressure) is critically 77 dependent on the starting frequency of resistance alleles in the population when new drugs 78 are deployed (1,2). If no such alleles are present when a novel drug is introduced, then there is 79 a waiting time for resistance alleles to arise. Furthermore, because the starting allele frequency 80 will be 1/(2N e ), where N e is the effective population size, the vast majority of resistance alleles 81 that arise will be lost due to genetic drift and fail to establish (2,3) ( Fig. 1) . The barrier to 82 establishment is particularly severe for recessive traits because these will be present in 83 heterozygotes at low frequency and therefore not exposed to selection. This effect, otherwise 84 known as "Haldanes's sieve" (4), may be particularly relevant for drug resistance evolution in 85 diploid pathogens, because resistance mutations in drug targets typically result in phenotypic 86 resistance only when two copies are present. However, if resistance alleles are already 87 segregating as standing variation in pathogen populations when drug treatment is initiated, 88 then there is no waiting time for mutations to arise. Furthermore, there is a high probability of 89 fixation and spread is rapid because many resistance alleles are present in homozygous 90 recessive genotypes and therefore exposed to selection. Hence, whether resistance alleles (or 91 alleles for other traits) arise de novo or are segregating as standing variation, is a central 92 question in evolutionary biology and public health, and key to predicting the effective "shelf 93 life" of new drug treatments (3,5). 94 There is growing evidence for resistance to anti-helminthics in several helminths infecting 95 humans, including Onchocerca volvulus (6), the filarial nematode causing river blindness, and in 96 soil transmitted helminths (hookworm, whipworm and Ascaris roundworms) (7) which 97 cumulatively infect over one billion people worldwide (8). However, perhaps the best 98 understood is oxamniquine resistance in schistosome blood flukes, for which the mechanism of 99 drug action and the genetic and molecular basis for drug resistance are now known. 100 Oxamniquine (OXA) kills Schistosoma mansoni, but is ineffective against two other major 101 schistosome species infecting humans (S. haematobium and S. japonicum) (9). OXA is a pro-102 drug that is activated by a schistosome sulfotransferase (SmSULT-OR) encoded on chromosome 103 6 (10). Loss-of-function mutations within SmSULT-OR result in resistance: only parasites that 104 are homozygous for resistance alleles are phenotypically resistant (OXA-R). We initially 105 identified the locus and mutation, a single amino acid deletion (p.E142del), underlying OXA-R 106 using a genetic cross involving a resistant parasite line selected from a parasite isolate from a 107 Puerto Rican patient in 1971 (11). Additionally we identified a second mutation (p.C35R) in S. 108 mansoni obtained from an incurable Brazilian patient (12). These two mutations result in 109 disruption of the active site of the SmSULT-OR and inability to activate OXA (10). Both 110 p.E142del and p.C35R, and two additional mutations resulting in truncated proteins, were 111 subsequently identified in a field survey of SmSULT-OR genetic variation of parasites from a 112 single Brazilian village (13). The combined allele frequency of these four resistant alleles was 113 1.85%. 114 OXA was widely used in the New World, where only S. mansoni is present, during the 1970s 115 to early 2000's (14), so the OXA-R alleles we observed in Brazil (13) could conceivably have 116 resulted from drug selection. In contrast, OXA saw minimal usage in Africa where both S. 117 haematobium and S. mansoni are present. In South America, an estimated 6 million doses of 118 OXA were used to treat the 7 million people infected with S. mansoni prior to 1987 (15 America. The central aim of this paper is to determine whether de novo mutation or standing 124 variation best explains OXA-R in S. mansoni populations. To do this we examined SmSULT-OR 125 genetic variation in Old World parasite populations where OXA treatment has been minimal. 139 We identified a total of 85 SmSULT-OR mutations across all three populations (West Africa, East 140 Africa and Middle East), including 76 coding mutations and 9 non-coding mutations (Supp. deletions. There were no differences in the density of mutations in the two exons (Fisher's 145 exact test, d.f.=1, p=0.09). The overall transition/transversion ratio was 1.94. Forty-three 146 percent (37/85 mutations) showed an average allele frequency greater than 5%. 147 Among the 85 mutations, we have previously found three coding and one non-coding 148 mutations in the New World (Caribbean and Brazil): the substitution p.P67L (g.200C>T), the 149 deletion p.E142del (g.4348_4350delGAA), the substitution p.L256W (g.4691T>G) and the 3' 150 untranslated region (UTR) substitution g.4720C>T (10,13). Just one of these mutations 151 (p.E142del) encodes a confirmed OXA-R allele. Frequencies of all mutations in each population 152 are shown in the supp. table 1. 153 We measured nucleotide diversity (π) in both New and Old World populations. Nucleotide 154 diversity was the highest in Oman (π = 0.02424 ± 2.4 × 10 -4 ) followed by East Africa (π = 0.00195 155 ± 2 × 10 -4 ), West Africa (π = 0.00126 ± 1.7 × 10 -4 ) and Brazil (π = 0.00021 ± 0.3 × 10 -4 ). If drug 156 pressure drives the changes at SmSULT-OR, we might expect to see signals of positive selection. 157 We examined sequence conservation by measuring proportions of non-synonymous difference 158 per non-synonymous site relative to synonymous changes per synonymous site (K a /K s ) between 159 S. mansoni and a S. rodhaini outgroup. K a /K s ranged from 0.20 -0.24 suggesting that changes at 160 non-synonymous sites are 4-5 times less abundant than at synonymous sites, consistent with 161 weak purifying selection. Similarly, the ratio of non-synonymous polymorphisms per non-162 synonymous site relative to synonymous polymorphisms per synonymous site (pN/pS) ranged 163 from 0.111 to 1.36 and none of these values were significantly greater than unity (Table 1) . 164 These tests did not provide evidence that SmSULT-OR is under positive selection. 165 166 3. In vitro tests and in silico evaluation of impact of mutations 167 We used three approaches to identify SmSULT-OR mutations that are likely to result in OXA-R. 168 a. Visual assessment 169 Some mutations have obvious deleterious effect on the protein by introducing premature stop 170 codons. This is the case for three mutations identified in SmSULT-OR. These mutations will 171 generate truncated proteins that do not contain the active site. Other mutations, such as 172 p.L179P, p.P225S or p.W120R, were either close enough to the OXA or the 3'-173 phosphoadenosine-5'-phosphosulfate (PAPS) binding sites or showed potential steric hindrance 174 or structural deformation likely to have an effect on protein activity. Other mutations, such as 175 p.A74T, p.P106S or p.Q176R, were on the surface of the protein, distant to any active site, and 176 therefore unlikely to have an impact. 177 b. Functional assay of OXA binding 178 We used an in vitro OXA activation assay to functionally assay the impact of mutations on 180 ( Fig. 3 ). The known resistant mutations, p.C35R and p.E142del, showed from zero to very low 181 level of OXA activation, as expected (10). p.L179P showed a similarly low level of activation. The 182 mutations p.S160L and p.P225S showed intermediate OXA activation: we conservatively classed 183 these as OXA sensitive alleles. p.P106S showed similar activity to the wild type and p.S160L. We 184 were able to produce recombinant protein p.W120R but all our attempts to fold this protein 185 were unsuccessful. This mutation clearly has a dramatic impact on protein stability as predicted 186 by visual inspection and thermodynamic modelling results (below). We considered this 187 mutation to be OXA-R. 188 c. Thermodynamic modelling 189 We used thermodynamic modelling to evaluate the potential impact of substitutions on protein 190 stability (indels such as p.E142del cannot be modelled). The difference in free enthalpy (ΔΔG) 191 ranged from -2.942 to 19.826 for the 37 mutations ( Fig. 4 ). Among those, p.L179P and p.C35R 192 which have the greatest impact on OXA activation ( Fig. 3) showed the second and third highest 193 ΔΔG, respectively. p.W120R, for which we were unable to fold recombinant protein, showed 194 the highest ΔΔG, consistent with a dramatic impact on stability. p.S160L and p.P225S showed 195 intermediate ΔΔG consistent with the results of the OXA activation assay. 196 In total, we identified 7 independent OXA-R mutations in Old and New World parasite 197 populations examined using these three approaches (Table 2, calling data on the first 3 Mb of the chromosome 6 (corresponding to 30,812 variable sites). 205 West African samples carried only two resistant variants (p.S12X and p.E142del). East African 206 samples carried five resistant variants, two of them at a frequency over 0.05 (p.W120R and 207 p.N171IfsX28). The p.W120R mutation was also found at high frequency in Middle East (0.065). 208 We found the highest frequency of OXA-R alleles in East Africa (14.91%, 17/114), followed by 209 the Middle East (6.25%, 14/224), West Africa (4.29%, 3/70), and Brazil (1.85%, 7/378). 210 Most parasites carried OXA-R alleles in the heterozygous state and are predicted to be OXA 211 sensitive. Heterozygous OXA-sensitive parasites were found in West and East Africa (8.6% and 212 24.6%, respectively), Middle East (13.4%) and in Brazil (1.06%). Parasites that are homozygous 213 for OXA-R alleles at SmSULT-OR (but not necessarily carrying the same resistant variant) are 214 OXA-R. We found homozygous parasites predicted to be phenotypically OXA-R at a frequency of 218 We used our phased data to investigate the haplotypes surrounding our resistant variant 219 (p.E142del) in the Old and New World (Caribbean) (Table 1) and to investigate whether these 220 resistant alleles derived from a common ancestor. This is of interest because it would suggest 221 that these alleles predate the slave trade. We identified an identical 102.5 kb haplotype block 241 Two lines of evidence support the view that standing variation is the source of OXA-R alleles in 242 schistosomes. First, we have indirect evidence: OXA-R alleles are geographically widespread in 243 Africa and the Middle East despite limited treatment with OXA (or hycanthone, its structural 244 analog; (18)) in these regions. Furthermore, that OXA-R alleles are found at high frequency in 245 East Africa, where there has been minimal use of OXA, while OXA-R alleles are found at low 246 frequency in Brazil, where OXA has been used extensively, is also consistent with the idea that 247 mutation and drift, rather than selection, explain the patterns of variation observed. The 248 second line of evidence is more direct: we showed that an OXA-R mutation, p.E142del, with an 
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Given the variation in OXA-R frequencies that we observe in different geographical samples, it is 265 interesting to examine the literature on clinical treatment efficacy of OXA for treating 266 schistosomiasis patients. Early trials of OXA to treat patients with intestinal schistosomiasis 267 resulted in multiple treatment failures in Egypt, East Africa and South Africa (23-27). As a 268 consequence, the WHO recommended use of higher doses of OXA in East Africa, compared 269 with West Africa (28) . Human host metabolism did not explain this lack of efficacy because the 270 OXA availability in blood was the same or higher in the East African patient populations than in 271 West African or South American populations (29, 30) . Therefore, the presence of resistant OXA-R parasites in S. mansoni suggests that OXA derivatives will result in imperfect cure rate 285 for this species, particularly in East Africa. However, the primary purpose of generating OXA 286 derivatives is to treat S. haematobium and S. japonicum, perhaps as a partner drug for 287 praziquantel (PZQ). Examining natural variation in homologous sulfotransferase genes from 288 these two species (ShSULT-OR and SjSULT-OR) to better understand the potential for resistance 289 evolution will be critical if OXA derivatives are to be developed to control these parasites. 290 291 4. Implications of standing variation for drug resistance evolution 292 Standing variation in drug resistance genes has a major impact on how fast resistance evolves 293 (2). If resistant alleles are already present in the population prior to treatment, drug resistance 294 has the potential to spread much more rapidly because there is no waiting time for a resistance 295 mutation to appear de novo ( Fig. 7A) (3). An increasing number of examples support this view. 296 The nematode Caenorhabditis elegans carries a large diversity of β-tubulin alleles allowing 297 worms to be resistant to benzimidazoles (32). Similarly, the extremely high level of genetic 298 diversity in the parasitic nematode Haemonchus contortus is responsible for the rapid 299 emergence of resistance to benzimidazoles and other drug classes: resistance was usually 300 detected within 10 years of drug introduction, consistent with standing variation or recurrent 301 mutation (33,34). In the filarial worm Onchocerca volvulus, standing variation appears to be 302 involved in resistance to ivermectin (6). Standing variation is also involved in herbicide 303 resistance in plants: resistance alleles from the weed Alopecurus myosuroides were identified in 304 plant collection almost 100 years before herbicides were used (35). Antibiotic resistance 305 provides particularly dramatic examples of standing variation: plasmids encoding multidrug 306 resistance were found in frozen bacteria isolated from the permafrost demonstrating that 307 antibiotic resistance plasmids were already present thousands of years ago (36,37). 308 Drug resistance in parasitic helminths infecting livestock or humans is now recognized as a 309 potential concern for control efforts, but was neglected for a long time using the argument that 310 the slow reproduction rate of worms would greatly delay resistance evolution (38). The 311 observation that resistance alleles exist as standing variation within multiple pathogen or 312 parasite populations in the absence of drug treatment suggests previous optimism about the 313 shelf life of drugs was poorly founded. If resistance alleles are already at relatively high 314 frequency in populations when new drugs are deployed, resistance may evolve extremely 315 rapidly (3,5). 316 In the case of OXA resistance, using an N e estimate of 65,000 (39), OXA-R alleles spread 317 from 15% starting frequency to fixation in 170 generations in 100% of simulations when 318 selection is strong (s=0.1). Assuming a generation time between 3 months and 1 year, this is 319 equivalent to a period of 42.5 to 170 years ( Fig. 7A ). However, if OXA-R alleles were evolving de 320 novo, simulations indicate that fixation will occur rarely (0.04% of the simulations) and this 321 would take 1,197 generations (corresponding to a period of 299.25 to 1,197 years) from the 322 time a mutation arises. We can use the observed frequency of OXA-R alleles segregating in East 323 African populations to make predictions about the spread of phenotypically resistant parasites 324 (i.e. those homozygous for OXA-R alleles) ( Fig 7B) . If we use a frequency of 10% resistant 325 parasites to denote unacceptable efficacy (this threshold is used for antimalarial drugs (40)) 326 then this threshold will be reached in 19 to 444 generations (4.75 to 444 years) using a range of 327 selection coefficients (from 0.01 to 0.2). The selection coefficients driving spread of drug 328 resistance alleles in schistosomes is not known, but the range we have used covers measured prediction, as we have done here. 358 PZQ is the only drug currently available to treat schistosomiasis and effort in mass drug 359 administration has recently been expanded 10 fold (48), with a target of administering 250 360 million treatments per year, increasing selective pressure for PZQ resistance. We suspect that 361 standing variation for PZQ resistance is also likely, because this trait is easy to select in the 362 laboratory. This has been done by several groups using independent laboratory populations, 363 and resistance has spread within very few generations (49-54), strongly suggesting that 364 resistance alleles were already present in these laboratory populations. Furthermore, the 365 laboratory populations used for selection were isolated before PZQ was available (23,55) and so 366 were not exposed to drug selection. Molecular markers for monitoring the frequency of PZQ-R Biomphalaria pfeifferi (Supp. table 2): 11 patients from 4 localities, 2 rats from 2 localities, 26 435 snails from 3 localities. 436 We obtained schistosome adult worms from naturally infected rats and from laboratory 437 infected mice. The mice were infected with cercariae from naturally infected snails or from 438 laboratory snails infected with miracidia isolated from stool samples. We collected miracidia 439 from stool samples as described in Moné et al. (61) . We exposed Biomphalaria pfeifferi snails to 3. DNA processing and library preparation 456 We amplified DNA and sequenced exomes from single miracidia preserved on FTA cards (1 457 miracidium per patient) for African samples or from DNA extracted from worms or cercariae for 458 Omani samples. FTA-preserved samples were processed following our published protocol (64). 459 Briefly we punched a 2 mm disc containing the miracidium from the FTA card, washed it with Because WGA reactions are non-specific, we performed qPCR on each sample from FTA 473 cards to quantify proportion of schistosome DNA (i.e., check for an excess of amplified DNA 474 from the environment (water, fecal matter, etc.)). We excluded samples that showed less than 475 100 schistosome genomes copies in 20 ng of DNA which were not suitable for subsequent 476 exome capture. We assessed genome copies by quantifyng the S. mansoni α-tubulin single copy 477 gene (64). 478 We prepared exome capture libraries on the selected African samples and on all the 479 successfully amplified Omani samples using the pre-capture pooling method of the SureSelect 480 XT 2 Target Enrichment System (Agilent) (64). Finally, we sequenced libraries on a HiSeq 2500 481 and data were demultiplexed using the Casava pipeline. 482 483 4. Alignment, variant calling and phasing 484 We aligned sequences as described in Le Clec'h et al. (64) . Briefly, we aligned data against the 485 v5 S. mansoni genome using BWA and SAMtools, realigned around indels using GATK, PCR 486 duplicates were marked using picard and Q-score were recalibrated using GATK. 487 To identify variants in the SmSULT-OR (Smp_089320) gene, we performed a variant calling 488 using FreeBayes (v1.1.0-46-g8d2b3a0) (65) in the first 3 Mb of the chromosome 6. We used a 489 minimum base quality (-q) of 20 and a minimum mapping quality (-m) of 30. We included 490 mutation sites identified previously (10,13) in order to genotype these sites specifically for 491 further comparison. We defined 4 populations: Caribbean (HR), West Africa (SN and NE), East 492 Africa (TZ) and Middle-East (OM). We excluded variants supported by less than 4 reads using 493 VCFtools (v0.1.14) (66). We then used vcf-subset from VCFtools to remove sites with reference 494 alleles only. We adjusted variant positions using vt normalize (v0.5772-60f436c3) (67). We 500 We performed all the genetics analysis using phased exome data. We handled the VCF data in R 501 (R v3.5.0 (69)) using the vcfR package (v1.8.0.9) (70) . We determined the longest haplotype 502 block from the samples carrying the p.E142del using a custom R code after filtering invariable 503 sites in these samples. We built the haplotype network using the R package poppr (v2.8.1) 504 (71,72) after selecting variants within the longest haplotype coordinates showing no more than 505 20% of missing data. We computed the frequency of the OXA-R allele using a custom R script 506 and functional annotation obtained through a custom bash script. 507 We generated haplotype sequences of the coding sequence only for the Old World samples 508 using the updated phased VCF data exported from R and the BCFtools (v1.2) (73). We 509 generated haplotypes of the South American samples from previous genotyping using a custom 510 bash script. We included the SmSULT-OR homologue sequence from S. rodhaini previously 511 identified (13). We aligned the haplotypes using Clustal Omega (v1.2.2) (74). We determined 512 nucleotide diversity, number of synonymous and non-synonymous sites using DnaSP software 513 (v6.12.01) (75). Populations were defined as described in the previous section. Scripts used to 514 analyze the data are available on Zenodo. 515 516 6. Recombinant SmSULT-OR protein production and OXA activation assay 517 We produced recombinant SmSULT-OR proteins following Chevalier et al. (13) . Briefly, 518 mutations were introduced in the cloned SmSULT-OR gene sequence (Smp_089320; GenBank 519 accession no. HE601629.1) and introduced into Escherichia coli for protein production. Proteins 520 were extracted from bacterial culture and purified on an affinity chromatography column. His-521 tag was removed using Tobacco etch virus (TEV) protease, the solution was dialyzed overnight 522 and passed through affinity chromatography again to remove His-tag and TEV protease. The 523 sample was loaded onto a GE-pre-packed Q anion exchange column and eluted, and the pooled 524 fractions were dialyzed overnight. The protein was finally concentrated at 10 mg.mL -1 . 525 We tested the impact of a subset of the mutations observed on OXA activation using an in 526 vitro assay (13). We tested the ability of recombinant SmSULT-OR proteins to activate OXA in a 527 protease inhibitor cocktail with sheared S. mansoni gDNA as a final target for the tritiated OXA 528 pre-mixed with ATP, MgCl 2 and PAPS co-factor. After 2.5 h of incubation at 37°C, the reaction 529 was stopped and DNA was extracted three times. Radioactivity in the remaining aqueous phase 530 containing the DNA and in water (blank) was counted in a liquid scintillation spectrometer. 531 Blank values were subtracted from sample values. We performed three independent reactions 532 for each recombinant protein. 533 534 We first visually assessed the scored mutations on the SmSULT-OR protein structure (PDB code 535 4MUB (10)) using the mutagenesis function of PyMol software (v2.3.0; Schrödinger, LLC). 536 We then used the Rosetta package (v3.9) to test the impact of scored mutations on protein 537 stability. We used the ddg_monomer application to compute the difference in free enthalpy 538 (ΔΔG) between the mutated (amino acid substitutions only) and the wild-type protein. The 539 higher the ΔΔG, the more unstable is the mutated protein. For this, we prepared ligand files 540 (OAQ and A3P) by downloading SDF files containing all ligand structures from SmSULT-OR 541 crystals available from the Protein Data Bank website. We modified SDF files to add hydrogens 542 using Openbabel (v2.4.0) (76), and generated params files using molfile_to_params.py from 543 Rosetta. We used the structure of SmSULT-OR to generate a constraint file using the 544 minimize_with_cst application and the convert_to_cst_file.sh script. We removed ligand 545 information from the constraint file. For each mutation, we finally generated a resfile and ran 546 the ddg_monomer application with 50 iterations and options adapted from the protocol 16 of 547 Kellogg et al. (77) . Scripts used to analyze the data are available on Zenodo. The code used for nucleic acid mutations indicates the sequence type (c = coding), the position, and the mutation type (X>Y = substitution of X 812 by Y, insN = insertion of N, delN = deletion of N, dup = duplication). The code used for amino acid mutations indicates the sequence type (p = 813 protein), the reference amino acid, the position, and finally the alternative amino acid, and when frame shift (fs) occurs, the position of the stop 814 codon (X) after the mutation. For details about the nomenclature, see Ogino et al. (79) . 815 a Data from Brazil were obtained in a previous study (13) and added for comparison. 
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